Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Verastem (VSTM) EPS (Weighted Average and Diluted) (2016 - 2026)

Verastem's quarterly EPS (Weighted Average and Diluted) came in at -$0.46 in Q1 2026, up 52.08% year-on-year from -$0.3 in Q1 2025, and down 58.62% quarter-over-quarter from -$0.29 in Q4 2025.

Verastem has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at -$0.46 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 52.08% year-over-year to -$0.46; the trailing twelve-month figure through Mar 2026 stood at -$2.72 (up 20.47% YoY), and the FY2025 full-year result was -$3.02, up 17.49% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.46, down from -$0.29 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.08 in Q1 2023, with the low at -$4.27 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.89, with a median of -$0.62 recorded in 2025.
  • Year-over-year, EPS (Weighted Average and Diluted) plunged 1475.0% in 2024 and jumped 81.29% in 2025.
  • Tracing VSTM's EPS (Weighted Average and Diluted) over 5 years: stood at -$4.27 in 2022, then soared by 75.88% to -$1.03 in 2023, then plunged by 50.49% to -$1.55 in 2024, then soared by 81.29% to -$0.29 in 2025, then slumped by 58.62% to -$0.46 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$0.46 (Q1 2026), -$0.29 (Q4 2025), and -$1.35 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -4.43
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 4.02
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.51
10 Verastem 425.60 Mn 243.93 Mn 15.90 Mn -0.46

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.46
Dec 31, 2025 -0.29
Sep 30, 2025 -1.35
Jun 30, 2025 -0.62
Mar 31, 2025 -0.96
Dec 31, 2024 -1.55
Sep 30, 2024 -0.60
Jun 30, 2024 -0.31
Mar 31, 2024 -1.26
Dec 31, 2023 -1.03
Sep 30, 2023 -0.75
Jun 30, 2023 -1.37
Mar 31, 2023 -0.08
Dec 31, 2022 -4.27
Sep 30, 2022 -0.09
Jun 30, 2022 -0.12
Mar 31, 2022 -0.09
Dec 31, 2021 -4.59
Sep 30, 2021 -0.13
Jun 30, 2021 -0.10
Mar 31, 2021 -0.09
Dec 31, 2020 -0.12
Sep 30, 2020 0.08
Jun 30, 2020 -0.14
Mar 31, 2020 -0.35
Dec 31, 2019 -0.51
Sep 30, 2019 -0.41
Jun 30, 2019 -0.57
Mar 31, 2019 -0.52
Dec 31, 2018 -0.37
Sep 30, 2018 -0.29
Jun 30, 2018 -0.30
Mar 31, 2018 -0.41
Dec 31, 2017 -0.47
Dec 31, 2016 -0.32